Fiche traitement
CAR-T
The First Affiliated Hospital of Soochow University • SEP
Suivi actif
Phase 2
Résumé
CAR-T est développé par The First Affiliated Hospital of Soochow University. Le traitement est actuellement en Phase 2. Il est associé à SEP. Son objectif thérapeutique principal est Thérapie cellulaire + Immunomodulation. Le statut actuel est : suivi actif.
À vérifier
Thérapie cellulaire + Immunomodulation
Phase 2
The First Affiliated Hospital of Soochow University
China
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.
2026-06-01
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 2
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Thérapie cellulaire
Immunomodulation
Confiance automatique : 80%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : cd20 → Immunomodulation, car-t → Thérapie cellulaire
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-06-01
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeTerminée
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 2
Études associées1
Publications associées36
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
40 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2017-06-01 | Début de l’étudeNCT03196830 | Registre d’essai clinique |
| 2024-01-31 | Fin de l’étude prévue / enregistréeNCT03196830 | Registre d’essai clinique |
| 2026-06-01 | Dernière mise à jour des donnéesCAR-T | Biomedical Watch |
| 2026-07-08 | PublicationRecent advances in universal chimeric antigen receptor T cell therapy. | Journal of hematology & oncology |
| 2026-07-08 | PublicationUniversal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. | Oncology research |
| 2026-07-10 | PublicationHigh Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T). | Cancers |
| 2026-07-10 | Publication2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology |
| 2026-07-10 | PublicationA new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report. | Rheumatology (Oxford, England) |
| 2026-07-14 | PublicationBCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. | Nature medicine |
| 2026-07-22 | PublicationTransfusion Support After CAR-T Cell Therapy: Real-World Patterns Across Commercial Products and Disease Groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine |
| 2026-08-13 | PublicationSingle-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy. | Med (New York, N.Y.) |
| 2026-08-13 | PublicationCD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. | HLA |
| 2026-08-13 | PublicationObecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. | The Annals of pharmacotherapy |
| 2026-08-13 | PublicationPSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. | Nature communications |
| 2026-08-13 | PublicationAdvances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic. | Journal of internal medicine |
| 2026-08-13 | PublicationBendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review. | Bone marrow transplantation |
| 2026-08-13 | PublicationComparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. | Transplantation and cellular therapy |
| 2026-08-13 | PublicationReal-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership. | Human gene therapy |
| 2026-08-13 | PublicationEfficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR-T Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. | European journal of haematology |
| 2026-08-13 | PublicationPretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. | Journal of cellular and molecular medicine |
| 2026-08-16 | PublicationImmune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. | Japanese journal of clinical oncology |
| 2026-08-16 | PublicationCRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia. | Chinese medical journal |
| 2026-08-16 | PublicationCAR-engineered cell therapies: current understandings and future perspectives. | Molecular biomedicine |
| 2026-08-16 | PublicationCoated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors. | Biomaterials |
| 2026-08-16 | PublicationFolate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies. | International immunopharmacology |
| 2026-08-16 | PublicationSustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation. | Biomaterials |
| 2026-08-16 | PublicationVitreoretinal Lymphoma: A Comprehensive Clinical Review and Current Standards in Management. | Journal of vitreoretinal diseases |
| 2026-08-16 | PublicationSpike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells. | bioRxiv : the preprint server for biology |
| 2026-08-16 | PublicationCCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. | International immunopharmacology |
| 2026-08-16 | PublicationBiomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring. | Pharmacology & therapeutics |
| 2026-09-03 | PublicationVery unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. | Clinica chimica acta; international journal of clinical chemistry |
| 2026-10-11 | PublicationHuman single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies. | BMC cancer |
| 2026-10-11 | PublicationIrradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy. | Haematologica |
| 2026-10-18 | PublicationEmerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives. | Molecular biology reports |
| 2026-10-18 | PublicationCholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. | Nature communications |
| 2026-10-18 | PublicationSafety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. | EClinicalMedicine |
| 2026-10-18 | PublicationPhase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. | Blood advances |
| 2026-11-01 | PublicationC-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. | American journal of hematology |
| 2026-11-08 | Création de l’enregistrementNCT03196830 | Registre d’essai clinique |
| 2026-11-08 | PublicationAutomated Production of Gene-Edited CAR-T Cells for People Living with HIV. | Human gene therapy |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT03196830 | CAR-T for R/R B-NHL | Phase 2 | COMPLETED | China | The First Affiliated Hospital of Soochow University |
Publications liées
36 publication(s)Publications liées
36 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Automated Production of Gene-Edited CAR-T Cells for People Living with HIV. Voir source | 42847201 | 10.1177/10430342261492461 | Human gene therapy | |
| C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. Voir source | 39351902 | 10.1002/ajh.27488 | American journal of hematology | |
| Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives. Voir source | 42709257 | 10.1007/s11033-026-12720-y | Molecular biology reports | |
| Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. Voir source | 38890370 | 10.1038/s41467-024-49495-4 | Nature communications | |
| Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. Voir source | 40386685 | 10.1016/j.eclinm.2025.103229 | EClinicalMedicine | |
| Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Voir source | 40811825 | 10.1182/bloodadvances.2024015763 | Blood advances | |
| Human single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies. Voir source | 42387444 | 10.1186/s12885-026-16352-0 | BMC cancer | |
| Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy. Voir source | 42610426 | 10.3324/haematol.2025.300165 | Haematologica | |
| Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. Voir source | 38697457 | 10.1016/j.cca.2024.119704 | Clinica chimica acta; international journal of clinical chemistry | |
| Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. Voir source | 42381271 | 10.1093/jjco/hyag103 | Japanese journal of clinical oncology | |
| CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia. Voir source | 40789664 | 10.1097/CM9.0000000000003588 | Chinese medical journal | |
| CAR-engineered cell therapies: current understandings and future perspectives. Voir source | 41559435 | 10.1186/s43556-025-00401-4 | Molecular biomedicine | |
| Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors. Voir source | 41903308 | 10.1016/j.biomaterials.2026.124143 | Biomaterials | |
| Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies. Voir source | 42322854 | 10.1016/j.intimp.2026.117042 | International immunopharmacology | |
| Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation. Voir source | 41936184 | 10.1016/j.biomaterials.2026.124187 | Biomaterials | |
| Vitreoretinal Lymphoma: A Comprehensive Clinical Review and Current Standards in Management. Voir source | 42602195 | 10.1177/24741264261474159 | Journal of vitreoretinal diseases | |
| Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells. Voir source | 41929125 | 10.64898/2026.03.26.713760 | bioRxiv : the preprint server for biology | |
| CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. Voir source | 42250288 | 10.1016/j.intimp.2026.116980 | International immunopharmacology | |
| Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring. Voir source | 42492739 | 10.1016/j.pharmthera.2026.109089 | Pharmacology & therapeutics | |
| Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy. Voir source | 41747738 | 10.1016/j.medj.2026.101026 | Med (New York, N.Y.) | |
| CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. Voir source | 42141373 | 10.1111/tan.70701 | HLA | |
| Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. Voir source | 42572849 | 10.1177/10600280261470829 | The Annals of pharmacotherapy | |
| PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Voir source | 39737899 | 10.1038/s41467-024-53220-6 | Nature communications | |
| Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic. Voir source | 42554215 | 10.1111/joim.70146 | Journal of internal medicine | |
| Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review. Voir source | 42332219 | 10.1038/s41409-026-02946-6 | Bone marrow transplantation | |
| Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. Voir source | 42341926 | 10.1016/j.jtct.2026.06.035 | Transplantation and cellular therapy | |
| Real-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership. Voir source | 42583745 | 10.1177/10430342261472597 | Human gene therapy | |
| Efficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR-T Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. Voir source | 42063324 | 10.1111/ejh.70205 | European journal of haematology | |
| Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. Voir source | 42528053 | 10.1111/jcmm.71296 | Journal of cellular and molecular medicine | |
| Transfusion Support After CAR-T Cell Therapy: Real-World Patterns Across Commercial Products and Disease Groups. Voir source | 42471153 | 10.1016/j.tracli.2026.07.008 | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | |
| BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Voir source | 41514039 | 10.1038/s41591-025-04170-z | Nature medicine | |
| High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T). Voir source | 41228344 | 10.3390/cancers17213551 | Cancers | |
| 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. Voir source | 41428622 | 10.4274/tjh.galenos.2025.2025.0330 | Turkish journal of haematology : official journal of Turkish Society of Haematology | |
| A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report. Voir source | 41984818 | 10.1093/rheumatology/keag195 | Rheumatology (Oxford, England) | |
| Recent advances in universal chimeric antigen receptor T cell therapy. Voir source | 40883768 | 10.1186/s13045-025-01737-8 | Journal of hematology & oncology | |
| Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. Voir source | 41179303 | 10.32604/or.2025.067445 | Oncology research |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-06-01
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.